📊 BMEA Key Takeaways
Is Biomea Fusion, Inc. (BMEA) a Good Investment?
Biomea Fusion is a pre-revenue biotech firm with catastrophic cash burn ($11.7M quarterly operating loss) against minimal revenue ($430K, declining 67% YoY), leaving no margin for safety in operations. Despite adequate cash reserves ($44.7M), the company's fundamentals show value destruction at all levels—negative ROE/ROA, zero commercial traction, and a burn rate that exhausts runway within 12-15 months without additional capital or revenue inflection.
Biomea Fusion’s fundamentals are very weak: the company is generating only modest revenue while posting extremely large operating and net losses, with deeply negative margins and returns on capital. Although the balance sheet is not debt-burdened and near-term liquidity is still adequate, the current cash burn appears too high relative to its cash balance, making the business heavily dependent on improving operating performance or raising additional capital.
Biomea Fusion, Inc. Key Strengths (BMEA)
- Debt-free balance sheet with zero leverage (Debt/Equity 0.00x)
- Strong liquidity position (Current Ratio 4.98x) for near-term obligations
- Adequate cash reserves ($44.7M) providing operational runway
- Strong current liquidity with a 3.18x current and quick ratio
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Cash balances of $46.64M still provide short-term operating flexibility
BMEA Stock Risks: Biomea Fusion, Inc. Investment Risks
- Acute cash burn of $11.7M per quarter with minimal revenue—reserves deplete in 12-15 months
- Revenue collapsed 67% YoY to $430K—no evidence of commercial product viability
- Extreme negative margins (Operating: -2971%, Net: -2887%) indicate unsustainable development-stage losses
- No visible path to profitability or commercial traction in SEC filings
- Operating and net margins are severely negative, indicating an unsustainable cost structure
- Operating cash flow and free cash flow are deeply negative, implying substantial ongoing cash burn
- Very low equity base relative to losses raises the risk of future dilution or financial strain
Key Metrics to Watch
- Quarterly revenue growth (reversed negative 67% decline)
- Operating cash burn rate (absolute dollars, trajectory toward breakeven)
- Cash runway (months until depletion at current burn rate)
- Clinical trial advancement or FDA milestone achievements
- Quarterly operating cash burn relative to cash and equivalents
- Revenue progression versus operating expense growth
Biomea Fusion, Inc. (BMEA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.98x current ratio provides a solid financial cushion.
BMEA Profit Margin, ROE & Profitability Analysis
BMEA vs Healthcare Sector: How Biomea Fusion, Inc. Compares
How Biomea Fusion, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biomea Fusion, Inc. Stock Overvalued? BMEA Valuation Analysis 2026
Based on fundamental analysis, Biomea Fusion, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biomea Fusion, Inc. Balance Sheet: BMEA Debt, Cash & Liquidity
BMEA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biomea Fusion, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.44 indicates the company is currently unprofitable.
BMEA Revenue Growth, EPS Growth & YoY Performance
BMEA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | $1.2B | -$5.9M | $-0.43 |
| Q2 2022 | $1.1B | -$5.9M | N/A |
| Q1 2022 | $1.1B | -$5.9M | N/A |
| Q3 2021 | $1.1B | -$293.0K | N/A |
| Q2 2021 | $1.1B | -$293.0K | N/A |
| Q1 2021 | $1.1B | -$398.0K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biomea Fusion, Inc. Dividends, Buybacks & Capital Allocation
BMEA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biomea Fusion, Inc. (CIK: 0001840439)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BMEA
What is the AI rating for BMEA?
Biomea Fusion, Inc. (BMEA) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BMEA's key strengths?
Claude: Debt-free balance sheet with zero leverage (Debt/Equity 0.00x). Strong liquidity position (Current Ratio 4.98x) for near-term obligations. ChatGPT: Strong current liquidity with a 3.18x current and quick ratio. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in BMEA?
Claude: Acute cash burn of $11.7M per quarter with minimal revenue—reserves deplete in 12-15 months. Revenue collapsed 67% YoY to $430K—no evidence of commercial product viability. ChatGPT: Operating and net margins are severely negative, indicating an unsustainable cost structure. Operating cash flow and free cash flow are deeply negative, implying substantial ongoing cash burn.
What is BMEA's revenue and growth?
Biomea Fusion, Inc. reported revenue of $430.0K.
Does BMEA pay dividends?
Biomea Fusion, Inc. does not currently pay dividends.
Where can I find BMEA SEC filings?
Official SEC filings for Biomea Fusion, Inc. (CIK: 0001840439) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BMEA's EPS?
Biomea Fusion, Inc. has a diluted EPS of $-0.17.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BMEA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Biomea Fusion, Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BMEA stock overvalued or undervalued?
Valuation metrics for BMEA: ROE of -66.3% (sector avg: 15%), net margin of -2,887.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BMEA's AI grade for 2026?
Our dual AI analysis gives Biomea Fusion, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BMEA's free cash flow?
Biomea Fusion, Inc.'s operating cash flow is $-11.7M, with capital expenditures of $0.0. FCF margin is -2,713.7%.
How does BMEA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,887.2% (avg: 12%), ROE -66.3% (avg: 15%), current ratio 4.98 (avg: 2).